Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Up – Here’s What Happened

Astellas Pharma Inc. (OTCMKTS:ALPMY) shares gapped up before the market opened on Tuesday. The stock had previously closed at $14.35, but opened at $15.13. Astellas Pharma shares last traded at $14.44, with a volume of 1,259 shares traded.

Analysts Set New Price Targets

Separately, Zacks Research lowered shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Astellas Pharma currently has a consensus rating of “Moderate Buy”.

Astellas Pharma Stock Performance

The stock has a 50 day simple moving average of $14.74 and a 200 day simple moving average of $14.48. The company has a quick ratio of 0.93, a current ratio of 1.20 and a debt-to-equity ratio of 0.16. The company has a market cap of $26.20 billion, a price-to-earnings ratio of 11.02 and a beta of 0.08.

About Astellas Pharma

Astellas Pharma Inc is a Japan-based pharmaceutical company that researches, develops, manufactures and commercializes prescription medicines for patients worldwide. Its portfolio focuses on areas of significant unmet medical need, including oncology, immunology, urology, ophthalmology, neuroscience and medical conditions related to genetic regulation.

The company’s products include XTANDI (enzalutamide) for certain prostate cancers, XOSPATA (gilteritinib) for acute myeloid leukemia, PADCEV (enfortumab vedotin-ejfv) for certain urothelial cancers, and PROGRAF (tacrolimus), an immunosuppressant used primarily to help prevent organ rejection following transplantation.